| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 200.41 | 3.3% | 1.3% |
| Total Income | 200.41 | 3.3% | 1.3% |
| Expenditure | 176.78 | 1.8% | 0.3% |
| PBT | 15.47 | 174.3% | 21.0% |
| Net Profit | 8.54 | 629.9% | 33.5% |
| OPM | 11.79% | 4.57pp | 1.41pp |
| NPM | 4.26% | 3.66pp | 2.06pp |
| EPS | 0.03 | 25.0% |
GoodRx Reports Q2 2026 Results, Raises Full-Year Guidance
06 Aug 2026 · 6 Aug, 1:46 am
Summary
GoodRx Holdings, Inc. announced its financial results for the second quarter of 2026, reporting revenue of $200.4 million, a slight decrease of 1% year-over-year. Despite the overall revenue dip, the company saw substantial growth in Pharma Direct revenue (up 76%) and subscription revenue (up 39%). Net income for the quarter was $8.5 million, with an Adjusted EBITDA of $63.7 million. Based on strong first-half performance, GoodRx is raising its full-year 2026 revenue and Adjusted EBITDA guidance.
Key Highlights
- 1
GoodRx reported second quarter 2026 revenue of $200.4 million, a 1% decrease year-over-year.
- 2
Pharma Direct revenue increased by 76% to $61.6 million, and subscription revenue grew by 39% to $28.5 million in Q2 2026.
- 3
Net income for the second quarter of 2026 was $8.5 million, with a net income margin of 4.3%.
- 4
Adjusted EBITDA for Q2 2026 was $63.7 million, representing a margin of 31.8%.
- 5
Net cash provided by operating activities significantly increased to $80.8 million in the second quarter of 2026.
- 6
The company is raising its full-year 2026 guidance for both revenue and Adjusted EBITDA.
Management Comments
Wendy Barnes
We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance. We believe this progress is accelerating our return to growth and strengthening the long-term durability of GoodRx.
Justin Fengler
We exceeded our expectations in the second quarter, with Pharma Direct revenue increasing 76% year-over-year and subscription revenue increasing 39% year-over-year. Based on our strong first-half performance, we are raising our full-year revenue and Adjusted EBITDA guidance.
Informational and educational content only. Not investment advice.